Skip to content

Effectiveness and safety study of catheter ablation of paroxysmal supraventricular tachycardia using three-dimensional mapping andconventional mapping techniques

Effectiveness and safety study of catheter ablation of paroxysmal supraventricular tachycardia using three-dimensional mapping andconventional mapping techniques

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014821
Enrollment
Unknown
Registered
2018-02-07
Start date
2017-04-01
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal supraventricular tachycardia

Interventions

CARTO group:CARTO method (CARTO system)
CARTO UNIV Group:CARTO UNIV method (CARTO UNIV system)
Control group (conventional measurement group):conventional measurement

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18- 78 years old male and female; 2. Previous history of tachycardia; 3. ECG recorded paroxysmal ventricular tachycardia,electrophysiological examination confirmed as AVNRT or AVRT; 4. Cardiac ultrasonography indicated that the cardiac function is normal; 5. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Post cardiac surgery at any time; 2. Previous medical history of arrhythmia radiofrequency catheter ablation or device implantation in heart; 3. Combined with acute coronary syndrome; 4. Infection: WBC =10.0×10^9/L or MEUT =75%; 5. Severe hepatorenal function impairment: ALT/AST> 3 times the upper limit of normal; serum creatinine >1.5 times the upper limit of normal; 6. Coagulation abnormality APTT =2 times the upper limit of normal or PLT =50.0×10^9/L; 7. Moderate or severe anemia: hemoglobin HGB=90 g/L; 8. Pregnant or breast-feeding; 9. Life expectancy less than 1 year; 10. Participated in other clinical trials within the past 3 months; 11. Investigator judged poor compliance as patients can not complete the study or follow up as required.

Design outcomes

Primary

MeasureTime frame
Immediate X-ray cumulative exposure dose and exposure time after operation;

Secondary

MeasureTime frame
Operation time;RFCA time;success rate;Surgical stress workload assessment scale;Follow-up success rate;Perioperative complications;All cardiovascularadverse events during the follow-up period;

Countries

China

Contacts

Public ContactHuang He

Renmin Hospital of Wuhan University

huanghe1977@hotmail.com+86 13986161018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026